Biogen
Search results
Ionis: A force for life. We are guided by world-class scientists and business leaders whose drive and passion to innovate is matched only by their commitment to deliver first-in-class and best-in-class medicines to the patients who need them. View 2023 Corporate Responsibility Report » Building Something Greater Than Ourselves.
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics.
We Are Transforming the Standard of Care and Pioneering New Markets. As the leader in RNA-targeted therapeutics for more than three decades, Ionis has focused every moment on advancing drug discovery, development, and providing hope for patients.
Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing.
A perpetual and efficient innovation machine. Our platform technology has served as a springboard for drug discovery and realized hope for patients with unmet needs. Our broad, diverse pipeline has more than 40 first-in-class and/or best-in-class medicines designed to treat a broad range of diseases. Review our pipeline »
Jun 25, 2024 · Ionis is planning additional regulatory filings for the treatment of FCS in the European Union this year. In addition to FCS, Ionis is evaluating olezarsen for the treatment of severe hypertriglyceridemia (sHTG) in three Phase 3 clinical trials – CORE, CORE2 and ESSENCE, all three of which completed enrollment in the first half of ...
Oct 4, 2023 · Ionis has made important progress in building our commercial and medical affairs organizations led by individuals with deep, relevant expertise across rare and broad diseases.
Ionis Pharmaceuticals, Inc. | 64,741 followers on LinkedIn. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases.
Amyotrophic Lateral Sclerosis. Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS) Visit Study Site » View All Studies. Search for a Study. Hide Tools » Therapeutic Conditions. Cardio-Renal. Neurological. Hematology. Other.
Get the latest Ionis Pharmaceuticals Inc (IONS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading...
